Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
190.60
-2.37 (-1.23%)
Official Closing Price
Updated: 7:00 PM EST, Feb 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
December 09, 2024
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom improvement and safety.
Via
Benzinga
Check Out What Whales Are Doing With ABBV
December 04, 2024
Via
Benzinga
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
December 04, 2024
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Via
Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
December 03, 2024
Via
Benzinga
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
December 03, 2024
Via
The Motley Fool
It’s Been A Tough Month For Healthcare Stocks
December 02, 2024
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Spotlight on AbbVie: Analyzing the Surge in Options Activity
November 29, 2024
Via
Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
November 26, 2024
Via
Benzinga
Market Whales and Their Recent Bets on ABBV Options
November 25, 2024
Via
Benzinga
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
December 01, 2024
Via
The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
November 30, 2024
Via
The Motley Fool
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
November 26, 2024
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.
Via
Benzinga
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
November 26, 2024
Via
The Motley Fool
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
November 23, 2024
Via
The Motley Fool
3 Dividend Stocks That Are Screaming Buys in November
November 23, 2024
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.
Via
The Motley Fool
Unpacking the Latest Options Trading Trends in AbbVie
November 20, 2024
Via
Benzinga
Where Will AbbVie Be in 5 Years?
November 19, 2024
Via
The Motley Fool
Smart Money Is Betting Big In ABBV Options
November 13, 2024
Via
Benzinga
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
November 22, 2024
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like.
Via
Investor's Business Daily
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
November 22, 2024
Via
Benzinga
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
November 19, 2024
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy.
Via
Talk Markets
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
November 18, 2024
Via
The Motley Fool
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
November 17, 2024
10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio.
Via
Benzinga
Seeking Beta
November 13, 2024
While the “Trump rally” appears to have just begun, one of its initial hallmarks is that investors want beta.
Via
Talk Markets
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
November 15, 2024
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
Via
Benzinga
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
November 15, 2024
The drugmaker has convincingly laid to rest the biggest threat to its top line.
Via
The Motley Fool
Abbvie Stock Price Analysis – A Post-Humira Dip, New Drug Hopes, And Election Buzz – Is Now The Time To Buy?
November 14, 2024
With the loss of Humira’s exclusivity and a recent dip in stock value, many are questioning the future trajectory of AbbVie stock.
Via
Talk Markets
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
November 14, 2024
A look at the moves made by Viking Fund management in the third quarter, including the exits and new stakes and fund's largest positions at the end of Q3.
Via
Benzinga
2 Dividend Stocks to Buy Hand Over Fist in November
November 14, 2024
These companies have solid businesses and excellent dividend growth track records.
Via
The Motley Fool
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
November 12, 2024
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.